![]() Hiromasa Suzuki, Ph.D., President and CEO of Miraca. Halbert and his team for their long-term investment in the world-class AP offerings that we have acquired,” said Dr. “Both companies are extremely well-positioned for the future, and we are grateful to Mr. The total purchase price was $725 million, including the repayment of the existing debt, subject to customary post-closing price adjustments. (“CDx,” a 100% subsidiary of CLS) and its subsidiaries and affiliates. 6, 2011, Miraca has acquired the AP business operated by Caris Diagnostics, Inc. As listed under the terms of the transaction, originally announced on Oct. (“CLS”), a privately-held company headquartered in Texas specializing in the development and commercialization of the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic technologies, today announced that they have completed the sale of CLS’ anatomic pathology (“AP”) business to Miraca. (“Miraca”), Japan’s largest clinical diagnostics and laboratory testing service provider, and Caris Life Sciences, Inc. ![]() Failure to obtain pre-authorization and physician referral may greatly reduce or eliminate your benefits.Tokyo, Japan & Irving, Texas – Novem– Miraca Holdings Inc. You or your physician may have to adhere to certain requirements in order to ensure maximum reimbursement.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |